Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Mehr anzeigen
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract...
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after...
– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.045 | 5.76923076923 | 0.78 | 0.8855 | 0.7 | 2817906 | 0.78206783 | CS |
| 4 | -0.0736 | -8.19051858446 | 0.8986 | 0.955 | 0.6603 | 2808015 | 0.77140839 | CS |
| 12 | -0.625 | -43.1034482759 | 1.45 | 1.49 | 0.6603 | 2552433 | 0.95021486 | CS |
| 26 | -1.285 | -60.9004739336 | 2.11 | 2.17 | 0.6603 | 2093043 | 1.21208846 | CS |
| 52 | -1.275 | -60.7142857143 | 2.1 | 3.7 | 0.6603 | 3134318 | 2.06224523 | CS |
| 156 | -17.625 | -95.5284552846 | 18.45 | 19 | 0.6603 | 2235464 | 4.32111572 | CS |
| 260 | -18.275 | -95.6806282723 | 19.1 | 23.03 | 0.6603 | 1752825 | 7.38862643 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
